# Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

> **NCT02113007** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 2 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Rituximab plus Temozolomide

## Key facts

- **NCT ID:** NCT02113007
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Closed early due to slow accrual.
- **Last updated:** 2017-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113007, "Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02113007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*